Kangenbei announced that its wholly-owned subsidiary Kangenbei of Inner Mongolia received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration regarding the new indications of Musk Tongxin Drops. The new indication for Musk Xiang Xin drip pills is heart failure with preserved ejection fraction. The registered classification is traditional Chinese medicine category 2.3. This medicine is a proprietary Chinese medicine independently developed and produced by Kangenbei, Inner Mongolia. It was approved and marketed in 2008. It is used for coronary artery disease stabilizing fatigue and pain relief. It is used for coronary artery disease stable stress angina pectoris, traditional Chinese medicine dialectical gas ischemia, and symptoms include chest pain, chest tightness, palpitations, shortness of breath, and fatigue.

Kangenbei announced that its wholly-owned subsidiary Kangenbei of Inner Mongolia received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration regarding the new indications of Musk Tongxin Drops. The new indication for Musk Xiang Xin drip pills is heart failure with preserved ejection fraction. The registered classification is traditional Chinese medicine category 2.3. This medicine is a proprietary Chinese medicine independently developed and produced by Kangenbei, Inner Mongolia. It was approved and marketed in 2008. It is used for coronary artery disease stabilizing fatigue and pain relief. It is used for coronary artery disease stable stress angina pectoris, traditional Chinese medicine dialectical gas ischemia, and symptoms include chest pain, chest tightness, palpitations, shortness of breath, and fatigue.